MedImmune scrambles back

MedImmune Inc.'s fortunes came full circle last week when the company received FDA approval to market RespiGam, its intravenous immune globulin against respiratory syncytial virus (RSV) disease, and announced a marketing partnership with Wyeth-Ayerst Laboratories.

The approval marks the end of a lengthy road for RespiGam and the company, which was lauded by several analysts as a "can't miss" proposition in 1993. With its CytoGam cytomegalovirus product on the market; RespiGam about to be approved; a deal with American Cyanamid to co-market the anti-infective Zosyn and develop additional products; and a deal in hand